PSMA positron emission tomography (PET) imaging is currently the most accurate and specific method in terms of imaging cells that present the molecular target, folate hydrolase, to an increased amount.
Especially in the case of prostate cancer, it has already been shown that, on the one hand, even small lesions measuring only a few millimeters can be detected even at low PSA levels after therapy of the primary tumor. On the other hand, our team was also able to show that this has a decisive influence on the further treatment decision and is thus often groundbreaking for the patient and the attending physician. Even before prostate cancer therapy, PSMA-PET often provided valuable, therapy-changing information.
With regard to PSMA-therapy imaging is of crucial importance as it shows which lesions are being treated, thus offering the possibility of a direct measurement and assessment of the therapeutic success.
Contact us to book your appointment.